19 February 2016 - PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-drug-pkc412-midostaurin-receives-breakthrough-therapy-designation-fda